Discover
APVO
Aptevo Therapeutics Inc.
4.42
1 x 4.06
2 x 4.47
bid
ask
+
0.00
0.00%
6 @ 08:19 AM
4.23 -0.19 (4.30%)
| Ytd | -53.13% | |
| 1y | -91.95% |
day range
3.68
52 week range
59.40
| Open | Prev Close | 4.42 | Low | High | Mkt Cap | 9.67M | |||
| Vol | 0.00 | Avg Vol | 56.57K | EPS | 1486.87 | P/E | N/A | Forward P/E | -0.83 |
| Beta | 1.66 | Short Ratio | 0.47 | Inst. Own | 11.36% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 4.69 | 200-d Avg | 11.37 | 1yr Est | 21.00 |
| Income Statement | |||
| Operating Expenses | 6.84M | ||
| Research and Development Expense | 3.92M | ||
| Selling, General and Administrative Expense | 2.91M | ||
| Operating Income | -6.84M | ||
| Net Income | -6.70M | ||
| Net Income Common Stock | -6.79M | ||
| Net Income Common Stock (USD) | -6.79M | ||
| Consolidated Income | -6.70M | ||
| Earnings per Basic Share | -6.41 | ||
| Earnings per Basic Share (USD) | -6.41 | ||
| Earnings per Diluted Share | -6.41 | ||
| Earning Before Interest & Taxes (EBIT) | -6.70M | ||
| Earning Before Interest & Taxes (USD) | -6.70M | ||
| Preferred Dividends Income Statement Impact | 97.00K | ||
| Weighted Average Shares | 1.06M | ||
| Weighted Average Shares Diluted | 1.06M | ||
| Balance Sheet | |||
| Cash and Equivalents | 14.53M | ||
| Cash and Equivalents (USD) | 14.53M | ||
| Current Assets | 15.98M | ||
| Property, Plant & Equipment Net | 3.92M | ||
| Total Assets | 19.90M | ||
| Debt Current | 892.00K | ||
| Total Debt | 4.42M | ||
| Current Liabilities | 4.76M | ||
| Debt Non-Current | 3.53M | ||
| Total Liabilities | 8.29M | ||
| Accumulated Retained Earnings (Deficit) | -281.91M | ||
| Shareholders Equity | 11.61M | ||
| Shareholders Equity (USD) | 11.61M | ||
| Assets Non-Current | 3.92M | ||
| Total Debt (USD) | 4.42M | ||
| Liabilities Non-Current | 3.53M | ||
| Trade and Non-Trade Payables | 890.00K | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 306.00K | ||
| Net Cash Flow from Financing | 871.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -7.09M | ||
| Issuance (Purchase) of Equity Shares | 871.00K | ||
| Net Cash Flow from Operations | -7.96M | ||
| Share Based Compensation | 57.00K | ||